The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Xenpozyme (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially life-threatening genetic disease.
- Read more about Xenpozyme approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/xenpozyme-approved-in-japan-first-and-only-approved-therapy-indicated-to-treat-acid-sphingomyelinase-deficiency
No comments:
Post a Comment